Trial Profile

A Phase 1 Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneously Administered Lirentelimab (AK002) in Adult Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lirentelimab (Primary) ; Lirentelimab (Primary)
Indications Atopic dermatitis; Chronic obstructive pulmonary disease; Conjunctivitis; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Keratoconjunctivitis; Urticaria
Focus Adverse reactions; Pharmacokinetics
Sponsors Allakos

Most Recent Events

24 Feb 2021 Status changed from active, no longer recruiting to completed.
11 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Feb 2021.
11 Dec 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com